{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"13"}],"units":"Participants"}],"description":"All patients that have received any amount of the combination anetumab ravtansine and pembrolizumab will be evaluable for toxicity. Please note this is different from the definition of evaluable for dose-limiting toxicity (DLT) where patients who cannot complete the planned dose due to reasons other than toxicity will be replaced.","groups":[{"description":"Phase 1 Cohort: Anetumab ravtansine \\& MK-3475","id":"OG000","title":"Phase 1 Cohort: Anetumab Ravtansine & MK-3475"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"Up to 2 years","title":"Phase I - Recommended Phase 2 Dose of Ametumab Ravtansine With Combination of Pembrolizumab","type":"PRIMARY","unitOfMeasure":"mg/kg IV"}